首页> 外文期刊>Asian journal of surgery >Long-term survival comparison between primary transplant and upfront curative treatment with salvage transplant for early stage hepatocellular carcinoma
【24h】

Long-term survival comparison between primary transplant and upfront curative treatment with salvage transplant for early stage hepatocellular carcinoma

机译:早期肝细胞癌原发移植与抢救性移植前期治疗的长期生存比较

获取原文
           

摘要

BackgroundWhether primary liver transplantation (PLT) or upfront curative treatment with salvage liver transplantation (SLT) is a better treatment option for early hepatocellular carcinoma (HCC) is controversial. This study aims to compare the long-term survival starting from the time of primary treatment between the two approaches for early HCC using propensity score matching (PSM) analysis.MethodsFrom 1995 to 2014, 175 patients with early HCC undergoing either PLT (n?=?149) or SLT (n?=?26) were retrospectively reviewed in a prospectively collected database. Patients' demographic data, tumor characteristics, short-term and long-term outcome were compared between two groups after PSM.ResultsAfter matching, the baseline characteristics were comparable between mPLT group (n?=?45) and mSLT group (n?=?25). The tumor recurrence rate after transplant was significantly higher in mSLT group than mPLT group (28% vs. 15.6%). Calculating from the time of primary treatment, the 1, 3, and 5-year overall survival rates were comparable between mPLT group (97.8%, 91.1% and 86.3%) and mSLT group (100%, 95% and 85%). However, the 1, 3, and 5-year recurrence-free survival rates were significantly better in mPLT group than mSLT group (95.6% vs. 90%, 86.6% vs. 80% and 84.3% vs. 70%). SLT approach and high pre-treatment serum alpha-fetoprotein level (>200?ηg/mL) were poor prognostic factors for recurrence-free survival after transplant.ConclusionsPLT may be a better treatment option for early HCC, whereas SLT approach for HCC should be cautiously considered under the circumstance of organ shortage.
机译:背景技术对于早期肝细胞癌(HCC),是否进行原发性肝移植(PLT)或采用挽救性肝移植(SLT)的前期治愈性治疗是更好的治疗选择。本研究旨在通过倾向评分匹配(PSM)分析比较两种早期HCC方法从初次治疗开始的长期生存率。方法1995年至2014年,有175例早期HCC患者接受了PLT(n =在预期收集的数据库中回顾性地回顾了[149]或SLT(n = 26)。比较PSM后两组患者的人口统计学资料,肿瘤特征,短期和长期预后。结果匹配后,mPLT组(n≥45)和mSLT组(n≥45)的基线特征相当。 25)。 mSLT组移植后的肿瘤复发率显着高于mPLT组(28%比15.6%)。从初次治疗时间算起,mPLT组(分别为97.8%,91.1%和86.3%)和mSLT组(分别为100%,95%和85%)的1年,3年和5年总生存率相当。但是,mPLT组的1年,3年和5年无复发生存率明显好于mSLT组(95.6%对90%,86.6%对80%和84.3%对70%)。 SLT方法和较高的治疗前血清甲胎蛋白水平(> 200?ηg/ mL)是移植后无复发生存的不良预后因素。结论PLT可能是早期HCC的更好治疗选择,而SLT方法应用于HCC。在器官短缺的情况下要谨慎考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号